Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 in Lupus Nephritis (China Phase II)
CTR20191068Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iscalimab in lupus nephritis (LN), sponsored by Novartis. Started Jun 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20191068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191068.